JPWO2023083209A5 - - Google Patents
Info
- Publication number
- JPWO2023083209A5 JPWO2023083209A5 JP2024527096A JP2024527096A JPWO2023083209A5 JP WO2023083209 A5 JPWO2023083209 A5 JP WO2023083209A5 JP 2024527096 A JP2024527096 A JP 2024527096A JP 2024527096 A JP2024527096 A JP 2024527096A JP WO2023083209 A5 JPWO2023083209 A5 JP WO2023083209A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- ligand compound
- pharmaceutically acceptable
- solvate
- ester
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111329108.1 | 2021-11-10 | ||
| CN202111329108 | 2021-11-10 | ||
| PCT/CN2022/130833 WO2023083209A1 (zh) | 2021-11-10 | 2022-11-09 | 一种靶向psma抗原的配体化合物及其螯合物与用于前列腺癌诊断和治疗的应用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024544870A JP2024544870A (ja) | 2024-12-05 |
| JP2024544870A5 JP2024544870A5 (https=) | 2025-12-12 |
| JPWO2023083209A5 true JPWO2023083209A5 (https=) | 2025-12-12 |
Family
ID=86335105
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024527096A Pending JP2024544870A (ja) | 2021-11-10 | 2022-11-09 | Ｐｓｍａ抗原を標的とするリガンド化合物及びそのキレート並びに前立腺癌の診断及び治療のための応用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20260069725A1 (https=) |
| EP (1) | EP4431503A1 (https=) |
| JP (1) | JP2024544870A (https=) |
| KR (1) | KR20240105380A (https=) |
| CN (1) | CN118176188A (https=) |
| AU (1) | AU2022384375A1 (https=) |
| CA (1) | CA3237743A1 (https=) |
| TW (1) | TW202321204A (https=) |
| WO (1) | WO2023083209A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118852044A (zh) | 2021-09-03 | 2024-10-29 | 晶核生物医药科技(南京)有限公司 | 一种肽脲素衍生物、含其的药物组合物及其应用 |
| CN117069670B (zh) * | 2023-07-31 | 2026-04-10 | 复旦大学附属华山医院 | 靶向psma的二聚体化合物及其衍生物和应用 |
| CN119954773A (zh) * | 2023-10-31 | 2025-05-09 | 苏州威智创科生物有限公司 | Psma化合物、包含其的药物组合物及其用途 |
| WO2025167998A1 (zh) * | 2024-02-06 | 2025-08-14 | 北京昌平实验室 | 膦酸酯骨架的psma靶向偶联物 |
| CN118221764A (zh) * | 2024-03-05 | 2024-06-21 | 苏州大学 | 一种双靶向分子探针及其制备方法与应用 |
| WO2026002208A1 (zh) * | 2024-06-28 | 2026-01-02 | 思路迪生物医药(上海)有限公司 | 前列腺特异性膜抗原小分子抑制剂及其放射性核素配合物的制备及应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11629201B2 (en) * | 2017-05-24 | 2023-04-18 | ITM Isotope Technologies Munich SE | PSMA-binding agents and uses thereof |
| US20200339625A1 (en) * | 2017-10-22 | 2020-10-29 | Provincial Health Services Authority | Novel radiometal-binding compounds for diagnosis or treatment of prostate specific membrane antigen-expressing cancer |
| CN114401947B (zh) * | 2019-06-21 | 2024-11-29 | 省卫生服务机构 | 靶向前列腺特异性膜抗原的放射性标记化合物 |
-
2022
- 2022-11-09 JP JP2024527096A patent/JP2024544870A/ja active Pending
- 2022-11-09 CA CA3237743A patent/CA3237743A1/en active Pending
- 2022-11-09 TW TW111142867A patent/TW202321204A/zh unknown
- 2022-11-09 US US18/708,905 patent/US20260069725A1/en active Pending
- 2022-11-09 AU AU2022384375A patent/AU2022384375A1/en active Pending
- 2022-11-09 CN CN202280074508.9A patent/CN118176188A/zh active Pending
- 2022-11-09 EP EP22892003.9A patent/EP4431503A1/en active Pending
- 2022-11-09 KR KR1020247014634A patent/KR20240105380A/ko active Pending
- 2022-11-09 WO PCT/CN2022/130833 patent/WO2023083209A1/zh not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7659268B2 (ja) | デュアルモード１８ｆ標識セラノスティック化合物及びその使用 | |
| JP7729609B2 (ja) | 診断および放射性核種治療剤としての前立腺特異的膜抗原（ｐｓｍａ）阻害剤 | |
| JP2025100545A (ja) | 鉛またはトリウム放射性核種に連結されたｐｓｍａ標的化化合物を含む錯体 | |
| US20200138985A1 (en) | Kit for labeling a prostate-specific membrane antigen ligand with a radioactive isotope | |
| JP7412487B2 (ja) | 放射性核種錯体を調製するための方法およびキット | |
| CN108290924B (zh) | 肽硫脲衍生物、含有其的放射性同位素标记化合物、和含有该化合物作为活性成分的用于治疗或诊断前列腺癌的药物组合物 | |
| CN1158133A (zh) | 肽衍生的放射性核素螯合剂 | |
| JP5690733B2 (ja) | ビスホスホン酸誘導体及びその放射性金属核種標識体 | |
| JP7541532B2 (ja) | 診断及び治療のための新規な放射性標識されたｃｘｃｒ４を標的とする化合物 | |
| JPWO2017150549A1 (ja) | 放射性標識薬剤 | |
| TW201008585A (en) | Novel [F-18]-labelled L-glutamic acid and L-glutamine derivatives (I), their use and processes for their preparation | |
| JP7447300B2 (ja) | 放射性金属と複合するＤＺ－１－Ｌｙｓ－ＤＯＴＡコンジュゲート及び使用 | |
| JPWO2021005125A5 (https=) | ||
| CN113105461A (zh) | 七甲基碳菁染料-交联四环胺螯合剂偶联物、复合物及其用途 | |
| JPWO2023083209A5 (https=) | ||
| JPWO2022212958A5 (https=) | ||
| EP0630264B1 (en) | Ligands for improving metal chelate formation kinetics | |
| JP2005523235A (ja) | 新規のキレート化剤およびその接合体、該キレート化剤およびその接合体の診断剤および治療剤としての合成および使用 | |
| JP3655312B2 (ja) | 血管疾患の診断のための錯化合物 | |
| KR101253100B1 (ko) | 폴리아자마크로사이클릭 화합물, 그 제조 방법 및 생의학적 적용 | |
| KR101389179B1 (ko) | 니트로이미다졸-아미노산 핵 저산소증 조영제 및 그 전구체 | |
| KR20030026153A (ko) | 간 기능 영상화를 위한 디설파이드 환원형 갈락토즈 결합혈청알부민 및 이를 포함한 방사성 동위원소 표지 화합물 | |
| CN101035567A (zh) | 新的锝和铼的络合物、其制备中所用的配体及其作为放射性药物的用途 | |
| KR20210046909A (ko) | 암 또는 염증질환의 진단 및 치료를 위한 사전표적 방사성의약품 | |
| KR20250011145A (ko) | 개선된 신장 청소율을 갖는 전립선-특이적 막 항원(psma) 리간드 |